Peter Attia· MD
but then as you pointed out there's a strategy now that says wait a minute what if we knock out the liver's ability to make apo little a and all of a sudden you wouldn't have an lp little a so what does that strategy look like and and where is that strategy in the pharmacologic pipeline in pretty early trials and of course any cell we're talking about the liver here if the liver is the primary site of production of apo little a and it is if we could mess with the genes through aso therapy we could probably stop a cell from making a given protein if we can stop the liver from making april protein little a if you don't have that you certainly the liver can't secrete it so it can attach to ldl particles transforming them into lp little a particles